BRPI0917412A2 - composto e uso de um composto - Google Patents

composto e uso de um composto

Info

Publication number
BRPI0917412A2
BRPI0917412A2 BRPI0917412A BRPI0917412A BRPI0917412A2 BR PI0917412 A2 BRPI0917412 A2 BR PI0917412A2 BR PI0917412 A BRPI0917412 A BR PI0917412A BR PI0917412 A BRPI0917412 A BR PI0917412A BR PI0917412 A2 BRPI0917412 A2 BR PI0917412A2
Authority
BR
Brazil
Prior art keywords
compound
Prior art date
Application number
BRPI0917412A
Other languages
English (en)
Inventor
Edward A Biehl
Santosh R D Mello
Original Assignee
Agents The University Of Texas System Board Of
Univ Southern Methodist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agents The University Of Texas System Board Of, Univ Southern Methodist filed Critical Agents The University Of Texas System Board Of
Publication of BRPI0917412A2 publication Critical patent/BRPI0917412A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0917412A 2008-08-15 2009-08-14 composto e uso de um composto BRPI0917412A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8944308P 2008-08-15 2008-08-15
US17786609P 2009-05-13 2009-05-13
PCT/US2009/053932 WO2010019911A2 (en) 2008-08-15 2009-08-14 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
BRPI0917412A2 true BRPI0917412A2 (pt) 2015-12-01

Family

ID=41669724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917412A BRPI0917412A2 (pt) 2008-08-15 2009-08-14 composto e uso de um composto

Country Status (9)

Country Link
US (1) US8680094B2 (pt)
EP (1) EP2328877A4 (pt)
JP (1) JP2012500220A (pt)
KR (1) KR20110050649A (pt)
CN (1) CN102159556A (pt)
AU (1) AU2009281748A1 (pt)
BR (1) BRPI0917412A2 (pt)
CA (1) CA2734305A1 (pt)
WO (1) WO2010019911A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856210B2 (en) 2010-09-02 2018-01-02 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
PL2651417T3 (pl) 2010-12-16 2017-08-31 Calchan Limited Pochodne pirolopirymidyny hamujące ASK1
CN103516915A (zh) * 2012-06-27 2014-01-15 百度在线网络技术(北京)有限公司 在移动终端通话过程中敏感词汇的替换方法、系统及装置
WO2014011754A1 (en) * 2012-07-10 2014-01-16 Amir Tamiz Novel 1, 4-benzoxazinone compounds
KR20140095202A (ko) * 2013-01-24 2014-08-01 목포대학교산학협력단 자죽염을 포함하는 알츠하이머병 예방용 조성물 및 자죽염의 제조방법
US11623946B2 (en) 2013-12-27 2023-04-11 National University Corporation Tokyo Medical And Dental University Diagnosis methods, diagnostic agents, and therapeutic agents against alzheimer's disease and frontotemporal lobar degeneration, and screening methods for these agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865818A (en) * 1973-10-24 1975-02-11 Squibb & Sons Inc Substituted benzoxazines
PL352680A1 (en) * 1999-06-03 2003-09-08 Knoll Gmbh Benzothiazinone and benzoxazinone compounds
JP2008231088A (ja) * 2006-10-30 2008-10-02 Santen Pharmaceut Co Ltd 1,4−ベンゾオキサジン−3−オン骨格を有する新規化合物

Also Published As

Publication number Publication date
KR20110050649A (ko) 2011-05-16
JP2012500220A (ja) 2012-01-05
AU2009281748A1 (en) 2010-02-18
EP2328877A4 (en) 2011-08-24
US20120094991A1 (en) 2012-04-19
EP2328877A2 (en) 2011-06-08
CA2734305A1 (en) 2010-02-18
US8680094B2 (en) 2014-03-25
CN102159556A (zh) 2011-08-17
WO2010019911A2 (en) 2010-02-18
WO2010019911A3 (en) 2010-05-27

Similar Documents

Publication Publication Date Title
BRPI0906186A2 (pt) composto e uso de um composto
BRPI0915134A2 (pt) composto, e, uso de um composto
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0905784A2 (pt) Uso de um composto esteramida, processos de preparação de um composto esteramida e composto esteramida
BRPI1007494A2 (pt) composto e uso do mesmo
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BR112012015392A2 (pt) "composto e uso cosmético de um composto"
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0821668A2 (pt) Uso
SMT201500218B (it) Composti aril-fenil-solfonammido-cicloalchile e loro uso
BRPI0918688A2 (pt) composto fluorescente e hidrofílico e uso de um composto fluorescente e hidrofílico
BR112012015366A2 (pt) compostos de fórmula (i), uso cosmético e uso de um composto
BRPI0716327A2 (pt) Composto de fenilpropionamida e uso
BRPI1007017A2 (pt) uso de um composto.
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI0919216A2 (pt) poliuretano, e, uso de um poliuretano
BRPI0814304A2 (pt) Uso de um composto metálico misto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired